Latest Administration News

Cycliq Group Ltd reports a robust Q2 FY2025 with a 15% rise in cash receipts to $1.92 million and strategic leadership appointments aimed at accelerating growth.

Cycliq Group Limited reported a robust net operating cash flow of $964,000 for the December 2024 quarter, bolstered by government grants and disciplined cost management. The company ended the period with a healthy cash balance of $1.12 million, signaling improved liquidity.

Prominence Energy reports steady progress in its uranium and gas exploration projects while pursuing new growth opportunities focused on capital efficiency and operational flexibility.

Basin Energy Limited's latest quarterly cash flow report reveals a $463,000 net cash outflow from operations and a tightening cash position, driven by sustained exploration and evaluation expenditures.

Kingsland Minerals secures a $2.56 million strategic investment from Quinbrook Infrastructure Partners, marking a pivotal step in advancing the Leliyn Graphite Project with binding offtake and renewable energy agreements.

Highfield Resources progresses its strategic partnership with Yankuang Energy, securing key regulatory approvals and updating financing arrangements for the Muga Potash mine, while navigating a court ruling on a mining concession.

InteliCare advances its AI-driven platform deployment across multiple Hardi Aged Care sites, while expanding its commercial pipeline and enhancing product capabilities.

InteliCare Holdings Limited reported a positive net cash flow of $30,000 for the December quarter, buoyed by a substantial government R&D rebate. The company ends the quarter with $1.26 million in cash, signaling operational stability amid ongoing funding evaluations.

Charger Metals NL's December quarter cash flow report reveals a $800,000 net cash decrease, driven by sustained exploration spending and limited operating receipts, leaving the company with $2.49 million in cash.

Terra Uranium has significantly expanded its land holdings in the Athabasca Basin through strategic option agreements with ATHA Energy Corp, setting the stage for a robust 2025 drilling campaign amid a recovering uranium market.

Latrobe Magnesium marks a year without lost time injuries and completes key construction phases, while navigating legal disputes and operational cost pressures.

Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.